These effects were mediated via the inhibition of the PI3K/AKT/mTOR pathway, which resulted in enhanced gemcitabine sensitivity in gemcitabine-resistant pancreatic cancer cells [70]. This evidence concerns the gene AKT1 and pancreatic neoplasm.